pre-IPO PHARMA

COMPANY OVERVIEW

Second Genome is a clinical stage pharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary drug discovery platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Gastrointestinal Disease
  • Inflammatory Disease
  • Liver Disease
  • Metabolic Disorders
  • Oncology

  • WEBSITE

    https://www.secondgenome.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    lightstone-ventures morgenthaler-ventures pfizer-ventures roche-venture-fund sr-one venbio


    PRESS RELEASES


    May 24, 2022

    Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease


    Apr 8, 2022

    Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity


    Mar 2, 2022

    Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration


    Feb 24, 2022

    Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)


    Feb 18, 2022

    Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)


    For More Press Releases


    Google Analytics Alternative